小剂量利妥昔单抗治疗难治性血小板减少性紫癜的临床效果  

Clinical Effect of Low-dose Rituximab in the Treatment of Refractory Thrombocytopenic Purpura

作　　者：董沙沙 赵永琴 DONG Sha-sha;ZHAO Yong-qin(First People's Hospital of Jining City, Jining, Shandong Province, 272029 China)

机构地区：[1]济宁市第一人民医院

出　　处：《系统医学》2019年第15期1-3,59,共4页Systems Medicine

摘　　要：目的分析在难治性血小板减少性紫癜中采取小剂量利妥昔单抗治疗的临床效果。方法自该院从2017年6月-2018年6月期间收治的64例难治性血小板减少性紫癜患者分为两组,对照组(n=32例)开展常规治疗,实验组(n=32例)开展小剂量利妥昔单抗治疗,比对对照组与实验组患者的临床治疗效果。结果干预后实验组难治性血小板减少性紫癜患者临床治疗有效率合计值(93.75%)对比对照组(75.00%),差异有统计学意义(χ2=4.266 7,P=0.038 8<0.05);干预后实验组难治性血小板减少性紫癜患者白细胞计数(7.22±0.22)×10^9/L、血红蛋白计数(122.51±0.31) g/L、血小板计数(88.5±3.21)×10^9/L对比对照组[(8.32±0.25)×10^9/L、(118.54±0.21) g/L、(66.54±2.92)×10^9/L]差异有统计学意义(P<0.05);干预后实验组与对照组难治性血小板减少性紫癜患者白细胞计数、血红蛋白计数、血小板计数和干预前比较,差异有统计学意义(P<0.05)。但两组性血小板减少性紫癜患者之间的不良反应计算值(12.50%vs 25.00%),差异无统计学意义(χ2=1.641 0,P=0.200 1>0.05)。结论将小剂量利妥昔单抗治疗用于治疗难治性血小板减少性紫癜中具有显著作用。Objective To analyze the clinical effect of low-dose rituximab in refractory thrombocytopenic purpura.Methods Sixty-four patients with refractory thrombocytopenic purpura admitted to our hospital from June 2017 to June2018 were selected and divided into two groups. The control group(n=32) underwent routine treatment. And the experimental group(n=32) was treated with low-dose rituximab. The clinical treatment effect of the control group and the experimental group were compared. Results After treatment, the total effective rate of clinical treatment in patients with refractory thrombocytopenic purpura(93.75%) was significantly higher than that in the control group(75.00%). The difference was statistically significant(χ2=4.266 7, P=0.038 8<0.05);intervention The white blood cell count of patients with refractory thrombocytopenic purpura(7.22±0.22)×10^9/L, hemoglobin count(122.51±0.31) g/L, platelet count(88.5±3.21)×10^9/L vs. control group [( 8.32±0.25)×10^9/L,(118.54±0.21) g/L,(66.54±2.92)×10^9/L] the difference was statistically significant(P<0.05);the experimental group and the control group refractory platelets after intervention The difference in white blood cell count, hemoglobin count, platelet count and pre-intervention in patients with reduced purpura was statistically significant(P<0.05). However, the calculated adverse reactions between the two groups of patients with thrombocytopenic purpura(12.50% vs 25.00%), the difference was not statistically significant(χ2=1.641 0, P=0.200 1>0.05). Conclusion Low-dose rituximab treatment has a significant effect in the treatment of refractory thrombocytopenic purpura.

关 键 词：小剂量 利妥昔单抗 难治性血小板减少性紫癜 临床效果 

分 类 号：R554.6[医药卫生—血液循环系统疾病]